Separate Safety Center Could Impair Oversight “Continuity” - Von Eschenbach

Creating "separate and independent" centers for drug approval and post-approval safety surveillance "would not improve the FDA's ability to fulfill its mission to protect the public health," FDA Acting Commissioner Andrew von Eschenbach asserted

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet